MaxCyte Q1 revenue falls

MaxCyte

12/05/2026 21:24

Overview

US cell-engineering platform's Q1 revenue fell 7% yr/yr, driven by lower core revenue

Net loss for Q1 narrowed compared to prior year

Company authorized $10 mln share repurchase program

Outlook

MaxCyte reiterates 2026 revenue guidance of $30 mln to $32 mln

Company expects 2026 core revenue of $25 mln to $27 mln

MaxCyte expects to end 2026 with at least $136 mln in cash, not including repurchases

Result Drivers

CORE REVENUE DECLINE - Core revenue, including instruments, consumables, licenses, and services, fell 25% yr/yr

SPL PROGRAM GROWTH - SPL Program-related revenue rose, with co citing clinical progress, including a partner starting a registrational study in Q1

Company press release: ID:nGNXbhY1L9

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
$9.7 mln
Q1 EPS
-$0.04
Q1 Net Income
-$4.8 mln
Q1 Gross Profit
$8.1 mln
Q1 Operating Expenses
$14.3 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for MaxCyte Inc is $4.50, about 450.9% above its May 11 closing price of $0.82

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)